Theravance Biopharma reported Q EPS of $0.06 versus the Zacks consensus of $0.44, missing by $0.38 (≈86% below expectations). This result compares with a year-ago loss of $0.05 and the clear earnings shortfall is likely negative for the stock, potentially prompting a 1–3% intraday move.
Theravance Biopharma reported Q EPS of $0.06 versus the Zacks consensus of $0.44, missing by $0.38 (≈86% below expectations). This result compares with a year-ago loss of $0.05 and the clear earnings shortfall is likely negative for the stock, potentially prompting a 1–3% intraday move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.70
Ticker Sentiment
